血管舒縮症狀市場規模、佔有率、成長分析（按治療類型、按分銷管道、按最終用戶、按地區）- 2025 年至 2032 年行業預測

血管運動症狀市場規模預計到 2023 年將達到 37.4 億美元，從 2024 年的 40.00 億美元成長到 2032 年的 68.2 億美元，預測期內（2025-2032 年）的複合年成長率為 6.9%。

根據市場洞察，血管舒縮症狀是月經女性報告最常見的問題，主要特徵是潮熱、盜汗和貧血。這些症狀會導致突然發燒和過度出汗，尤其是在頸部、臉部和前額。心悸的頻率和強度也有很大差異，特別是在停經後的頭兩年，這可能是一個特別的挑戰。對許多女性來說，這些令人衰弱的症狀可能是永久性的，凸顯了月經經驗的個人方面。此外，多方​​面的神經系統症狀的複雜性凸顯了需要製定個人化解決方案來解決女性在不斷變化的社會動態中度過這段過渡時期時所面臨的獨特挑戰。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

血管舒縮症狀市場規模（依治療類型及複合年成長率）（2025-2032）

• 市場概覽
• 雌激素
• 孕酮
• 組合
• 非處方激素
• 抗憂鬱症
• 其他

血管舒縮症狀市場規模（依分銷管道分類）及複合年成長率（2025-2032）

• 市場概覽
• 醫院藥房
• 零售藥局
• 藥局

血管舒縮症狀市場規模（依最終用戶和複合年成長率分類）（2025-2032）

• 市場概覽
• 醫院和診所
• 專業中心
• 其他

血管舒縮症狀市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• TherapeuticsMD（United States）
• Mithra Pharmaceuticals（Belgium）
• KaNDy Therapeutics（United Kingdom）
• Fervent Pharmaceuticals（United States）
• Astellas Pharma（Japan）
• Sojournix（United States）
• Mitsubishi Tanabe Pharma（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Pfizer Inc.（United States）
• Hikma Pharmaceuticals PLC（United Kingdom）
• Dr. Reddy's Laboratories Ltd.（India）
• AbbVie Inc.（United States）
• Endo Pharmaceuticals PLC（Ireland）
• Novartis AG（Switzerland）
• Wockhardt（India）
• Bayer AG（Germany）
• Eli Lilly and Company（United States）
• Sun Pharmaceutical Industries Ltd.（India）
• Alembic Pharmaceuticals Limited（India）
• Zydus Group（India）

結論和建議

Vasomotor Symptoms Market size was valued at USD 3.74 billion in 2023 and is poised to grow from USD 4.0 billion in 2024 to USD 6.82 billion by 2032, growing at a CAGR of 6.9% during the forecast period (2025-2032).

Market insights reveal that vasomotor symptoms are the most prevalent issues reported by women during menstruation, primarily characterized by hot flashes, night sweats, and anemia. These symptoms can lead to sudden sensations of heat and excessive sweating, particularly on the neck, face, and forehead. The frequency and intensity of heart palpitations also exhibit significant variability, especially during the first two years of menopause, marking this period as particularly challenging. For many women, these debilitating symptoms may become permanent, underlining the individual aspects of menstrual experiences. Furthermore, the complexity of multidimensional neurological symptoms emphasizes the necessity for tailored solutions to address the unique challenges faced by women navigating this transitional phase amidst evolving social dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Vasomotor Symptoms market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Vasomotor Symptoms Market Segments Analysis

Global Vasomotor Symptoms Market is segmented by Therapy Type, Distribution Channel, End User and region. Based on Therapy Type, the market is segmented into Estrogen, Progesterone, Combination, OTC hormone, Anti-Depressants and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Drug Stores. Based on End User, the market is segmented into Hospitals and Clinics, Specialty Centers, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Vasomotor Symptoms Market

Research and development (R&D) efforts and clinical trials are crucial in enhancing our comprehension of the mechanisms behind neurological symptoms, such as physiological changes and genetic mutations. This deeper insight can lead to the creation of more precise and effective therapies. As researchers delve into the complexities of neurological disorders through clinical trials, they contribute significantly to the market's strong compound annual growth rate (CAGR). These trials not only broaden the spectrum of available treatments but also stimulate market expansion by introducing groundbreaking therapeutic solutions, thereby driving advancements in the Vasomotor Symptoms market.

Restraints in the Vasomotor Symptoms Market

The Vasomotor Symptoms market faces significant constraints due to the high expenses linked with many treatment options. Market participants frequently allocate considerable resources towards developing innovative treatment strategies aimed at enhancing recovery outcomes, which consequently drives up overall costs. These hefty investments in research, development, and production lead to increased prices associated with different treatment modalities. Although these advancements offer the potential for improved patient outcomes and effectiveness of therapies, the associated higher costs create obstacles to the overall growth of the market, limiting accessibility and affordability for patients seeking relief from vasomotor symptoms.

Market Trends of the Vasomotor Symptoms Market

The vasomotor symptoms (VMS) market is experiencing notable growth, fueled by the introduction of innovative interventions and treatments that enhance awareness of these symptoms-primarily among women experiencing menopause. As awareness rises, more women are actively seeking effective relief, expanding the market significantly. Companies that specialize in pioneering new therapies or products have a distinct opportunity to gain a competitive edge, particularly if they succeed in establishing their offerings as the preferred choice among healthcare providers and patients alike. This trend suggests a vibrant, evolving marketplace characterized by heightened demand for effective VMS management solutions.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Vasomotor Symptoms Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Estrogen
• Progesterone
• Combination
• OTC hormone
• Anti-Depressants
• Others

Global Vasomotor Symptoms Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Retail Pharmacy
• Drug Stores

Global Vasomotor Symptoms Market Size by End User & CAGR (2025-2032)

• Market Overview
• Hospitals and Clinics
• Specialty Centers
• Others

Global Vasomotor Symptoms Market Size & CAGR (2025-2032)

• North America (Therapy Type, Distribution Channel, End User)
  • US
  • Canada
• Europe (Therapy Type, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Distribution Channel, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• TherapeuticsMD (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mithra Pharmaceuticals (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KaNDy Therapeutics (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fervent Pharmaceuticals (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sojournix (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo Pharmaceuticals PLC (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wockhardt (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alembic Pharmaceuticals Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Group (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations